107 Shares in Stryker Co. (NYSE:SYK) Bought by Crews Bank & Trust

Crews Bank & Trust bought a new stake in Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 107 shares of the medical technology company’s stock, valued at approximately $39,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Dunhill Financial LLC increased its position in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Stryker in the third quarter valued at approximately $36,000. HBW Advisory Services LLC acquired a new position in shares of Stryker during the 3rd quarter worth approximately $42,000. Hara Capital LLC bought a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. Finally, Grove Bank & Trust boosted its holdings in shares of Stryker by 84.8% in the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after buying an additional 56 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by company insiders.

Stryker Price Performance

Stryker stock opened at $390.90 on Friday. The firm has a market cap of $149.02 billion, a PE ratio of 50.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock’s fifty day moving average price is $376.68 and its two-hundred day moving average price is $362.81. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 EPS. As a group, research analysts expect that Stryker Co. will post 13.53 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date was Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is 43.30%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SYK. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday. Barclays upped their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Citigroup upped their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $419.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.